drugset / Trial / NCT05232409
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
Timeline
- Start
- 2022-04-17
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zeaxanthin | Small molecule | 2 mg/kg | Oral |
| Subject | Zeaxanthin | Small molecule | 4 mg/kg | Oral |
| Subject | Zeaxanthin | Small molecule | 6 mg/kg | Oral |
| Subject | Zeaxanthin | Small molecule | 8 mg/kg | Oral |
| Background | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |